Advocacy Pays Off for ASCs - Takeaways - MDSpire

Advocacy Pays Off for ASCs

At the Outpatient Ophthalmic Surgery Society’s “OOSS Perspective 2026” symposium in Washington, DC, the organization's Washington counsel, Michael Romansky, JD, delivered an update on reimbursement, regulatory developments, and advocacy priorities affecting ophthalmic ambulatory surgery centers (ASCs).

  • By

  • Jennifer Ford, content director

  • Jennifer Ford, content director

  • May 1, 2026

  • 4 min

Share

  • 1

    Michael Romansky highlighted a 3.4% increase in ASC payments for 2026, reversing an initial proposed reduction, benefiting ASCs by approximately $150 million.

  • 2

    OOSS advocates for broader definitions of non-opioid drugs eligible for separate payment, aiming to include inflammation treatments in reimbursement policies.

  • 3

    The Outpatient Surgery Access Act of 2026 was introduced to address longstanding reimbursement concerns, encouraging OOSS members to advocate for its support.

  • 4

    OOSS emphasizes the importance of compliance with CMS regulations, warning that non-participation in prior-authorization projects may lead to non-payment.

  • 5

    Romanksy urged continued member engagement in advocacy, stating that visualizing ASC facilities can effectively communicate their value to legislators.

Original Source(s)

Advocacy Pays Off for ASCs

  • by Jennifer Ford, content director, Jennifer Ford, content director

  • May 1, 2026

Related Content

How to Stay at the Forefront of Ophthalmology

Forty-four years in, Heaton Eye is still learning, but its foundation hasn't changed. "We believe in the technologies we offer, we prepare our team for success, and we let the outcomes do the rest."

Optegra Showcases Drop-Free Cataract Surgery Outcomes

Award-winning Optegra data on drop-free cataract surgery sparks interest at SECOIR 2026

  • June 11, 2026

  • 2 min
IL-6 Inhibitor Vamikibart Shows Efficacy Signals in DME Trial

At ARVO 2026, Arshad M. Khanani, MD, MA, FASRS, presented phase 2 data on vamikibart, an IL-6 inhibitor, in diabetic macular edema.